title: [Management of hereditary ovarian cancer].
abstract: Mutations in BRCA1 and BRCA2 genes account for the majority of hereditary breast and ovarian cancers. Approximately 10% of cases of ovarian cancer are due to germline mutations in BRCA1 and BRCA2. Ovarian cancer associated with BRCA1 and BRCA2 mutations has a distinct histological phenotype. This type of cancer is predominantly of serous or endometrioid histology and is high grade. Patients with BRCA1 or BRCA2 mutations should be offered risk-reducing salpingo-oophorectomy by age 40 years, or when childbearing is complete. Nowadays there are no differences between the treatments provided for sporadic and hereditary ovarian cancer, although there are indications that targeted therapy is effective in women with BRCA1/BRCA2-associated tumors. Retrospective studies reveal a high level of sensitivity to platinum agents in BRCA-associated tumors and initial trials show good efficacy and tolerability for polyADP-ribose polymerase inhibitors in mutation carriers with advanced ovarian cancers. These agents might also potentially be used in chemoprevention. Authors review the current management of hereditary ovarian cancer.
authors.affiliation: Semmelweis Egyetem, Általános Orvostudományi Kar I. Szülészeti és Nőgyógyászati Klinika Budapest Baross u. 27. 1088. joogabor@hotmail.com
authors.forename: József Gábor
authors.initials: JG
authors.lastname: Joó
authors.forename: Szabolcs
authors.initials: S
authors.lastname: Ládi
authors.forename: B Zsolt
authors.initials: BZ
authors.lastname: Nagy
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Langmár
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018394:CA-125 Antigen / Q000378:metabolism; D019175:DNA Methylation; D055088:Early Detection of Cancer / Q000379:methods / Q000592:standards / Q000639:trends; D005187:Fallopian Tubes / Q000601:surgery; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D018095:Germ-Line Mutation; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000145:classification / Q000453:epidemiology / Q000235:genetics* / Q000601:surgery / Q000628:therapy*; D010052:Ovariectomy; D057285:Precision Medicine / Q000379:methods / Q000592:standards / Q000639:trends; D018570:Risk Assessment; D012307:Risk Factors; D025521:Tumor Suppressor Proteins / Q000378:metabolism; D044767:Ubiquitin-Protein Ligases / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D035683:MicroRNAs; D025521:Tumor Suppressor Proteins; C102449:BARD1 protein, human; D044767:Ubiquitin-Protein Ligases